- ACELYRIN stockholders to receive 0.4814 shares of Alumis (ALMS, Financial) for each share owned, resulting in 48% ownership of the merged company.
- The combined entity is expected to have a pro forma cash position of $737 million, providing funding into 2027.
- Special stockholder meetings scheduled for May 13, 2025, with merger completion expected in Q2 2025.
Alumis Inc. (NASDAQ: ALMS) and ACELYRIN, Inc. have announced an amended merger agreement that revises the ownership terms between the two companies. Under the new terms, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each ACELYRIN share they hold. This adjustment results in Alumis stockholders owning approximately 52% of the combined entity, while ACELYRIN stockholders will own 48%.
The merger aims to form a leading clinical-stage immunology company with improved financial flexibility. The newly combined company is projected to have a pro forma cash position of approximately $737 million as of December 31, 2024, which is expected to support operations and development programs through 2027.
The boards of both companies have unanimously approved the transaction, and significant stockholder support has been secured, with 62% of Alumis and 24% of ACELYRIN shareholders having already agreed to the deal terms. Special stockholder meetings for both companies are scheduled for May 13, 2025, and the merger is anticipated to be finalized in the second quarter of 2025, pending stockholder approval and standard closing conditions.
